Fatigue Among the Most Common Toxicities in TKI Treatment

Share this content:
Cancer-related fatigue remains one of the most common toxicities in RCC treated with TKIs.
Cancer-related fatigue remains one of the most common toxicities in RCC treated with TKIs.

Cancer-related fatigue (CRF) remains one of the most common toxicities in patients with renal cell carcinoma (RCC) treated with tyrosine kinase inhibitors (TKIs) and should be properly recognized, according to a recent study published in the Journal of Pain and Symptom Management.

Deepa Anand, MD, and Carmen Escalante, MD, of the MD Anderson Cancer Center in Houston looked at patient data pulled from articles published in PubMed, Ovid, Embase, and MEDLINE between 1975 and 2014.

They conducted a narrative review with regards to incidence, pathophysiology, and management of CRF in patients with RCC who had undergone targeted therapy with TKIs.

“Although evolving data suggest these drugs may be beneficial in RCC, they are associated with significant toxicities,” the authors noted.

They concluded that CRF was one of the most common TKI toxicities in patients with metastatic RCC, and is often the dose-limiting toxicity.

RELATED: Alternate Sunitinib Schedules May Benefit Some with Metastatic Renal Cell Carcinoma

Non-pharmacological and pharmacologic interventions may me necessary in the management of TKI-related CRF.

“It is important to recognize this common, yet frequently underdiagnosed complication and initiate appropriate management strategies, in order to increase the likelihood for optimal outcomes,” they concluded.

Reference

  1. Anand, Deepa, MD, et al. "Ongoing Screening and Treatment to Potentially Reduce TKI-Related Fatigue in Renal Cell Carcinoma." Journal of Pain and Symptom Management. DOI: http://dx.doi.org/10.1016/j.jpainsymman.2015.02.007. [epub ahead of print]. February 19, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters